SINTX Technologies (SINT) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
12 Jun, 2026Executive summary
Annual meeting scheduled for September 4, 2025, with voting on five key proposals, including director elections, auditor ratification, executive compensation, a new equity incentive plan, and potential adjournment to solicit more proxies.
Shareholders of record as of July 11, 2025, are eligible to vote in person or by proxy, with multiple voting methods available.
Proxy materials, annual report, and voting instructions are accessible online and by mail.
Voting matters and shareholder proposals
Election of two Class II directors for terms expiring in 2028.
Ratification of Tanner LLC as independent auditor for 2025.
Advisory vote on executive compensation (say-on-pay).
Approval of the 2025 Equity Incentive Plan authorizing up to 700,000 shares and annual increases.
Approval for adjournment of the meeting if more proxies are needed.
Shareholder proposals for the 2026 meeting must be submitted by April 9, 2026, following SEC and bylaw requirements.
Board of directors and corporate governance
Board consists of six members divided into three staggered classes; majority are independent under Nasdaq rules.
Board committees include Audit, Compensation, and Corporate Governance/Nominating, all comprised of independent directors.
Board and committee meetings had high attendance in 2024; governance matters addressed in full board meetings.
Shareholders owning at least 5% for one year may recommend board nominees.
Latest events from SINTX Technologies
- Registering 5.8M shares for resale; faces Nasdaq compliance risk and potential dilution.SINT
Registration filing25 Jun 2026 - Silicon nitride implants disrupt extremity care with infection resistance and rapid market adoption.SINT
LD Micro Invitational XVI15 Jun 2026 - Q1 2025 net loss was $2.3M, but cash nearly doubled as focus shifted to medical devices.SINT
Q1 202512 Jun 2026 - FDA clearance, first product revenue, and cost reductions drive improved results.SINT
Q3 202512 Jun 2026 - 2024 revenue rose 10% to $2.9M, but net loss increased to $11.0M amid restructuring.SINT
Q4 202412 Jun 2026 - Revenue fell sharply as the company pivots to higher-margin medical devices, but liquidity risks persist.SINT
Q4 202512 Jun 2026 - Q2 2024 saw revenue growth, narrowed losses, a reverse split, workforce cuts, and a $4.5M impairment.SINT
Q2 202412 Jun 2026 - Shareholders will vote on director election, auditor, executive pay, and expanding the equity plan.SINT
Proxy filing12 Jun 2026 - Q3 2024 net loss widened due to a $4.5M impairment and workforce reduction amid a strategic review.SINT
Q3 202412 Jun 2026